Good afternoon, and welcome to the Sangamo Therapeutics Fourth Quarter and Full Year 2025 Teleconference Call. Please be advised that today's conference is being recorded. I would now like to turn the ...
Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
Hosted on MSN
Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks
CEO Alexander Macrae stated that "Sangamo continued to make significant pipeline progress in 2025 and into the first quarter of '26. Set against a backdrop of regulatory and market uncertainty and ...
Abstract: Pan-cancer intratumour heterogeneity (ITH) characteristics and their relationship with clinical prognosis have not been fully investigated. In this study ...
TORONTO, March 26, 2026 (GLOBE NEWSWIRE)-- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Sangamo missed EPS and revenue forecasts significantly, indicating financial challenges. The stock saw a 9.04% rise in aftermarket trading despite the earnings miss. Strategic partnerships and capital ...
Sangamo Therapeutics reported disappointing earnings for Q4 2025, with an EPS of -$0.11, missing the forecasted -$0.01 by a substantial margin. Revenue also fell short, reaching $14.23 million against ...
Welcome to this tutorial notebook that will go through the fitting and evaluation of Normative models with a Hierarchical Bayesian Regression (HBR) model using a Normal likelihood. Let’s jump right in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results